Paul Baas, MD, PhD, on Mesothelioma: First-Line Nivolumab Plus Ipilimumab vs Chemotherapy

Paul Baas, MD, PhD, of the Netherlands Cancer Institute, discusses results of the CheckMate 743 trial, which suggests nivolumab plus ipilimumab should be considered the new standard of care in first-line treatment of unresectable malignant pleural mesothelioma, regardless of the histology subtype (Abstract 3).

Related Videos

Lung Cancer

The ASCO Post Staff

Misako Nagasaka, MD, on NSCLC: Sintilimab, Pemetrexed, and Platinum as First-Line Therapy

Misako Nagasaka, MD, of the Barbara Ann Karmanos Cancer Institute, discusses results of the ORIENT-11 trial, which showed that, although sintilimab ...

Lung Cancer

COVID-19

The ASCO Post Staff

Marina C. Garassino, MD, on COVID-19 and Thoracic Malignancies: TERAVOLT Registry

Marina C. Garassino, MD, of the Istituto Nazionale dei Tumori di Milano, discusses the global registry she and her colleagues created to track and a...

Lung Cancer

The ASCO Post Staff

Leora Horn, MD, on NSCLC: Ensartinib vs Crizotinib in ALK–Positive Disease

Leora Horn, MD, of Vanderbilt University, discusses phase III results from the eXalt3 trial, which suggest that ensartinib, a novel, next-generation...